H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation

Jean François Lambert, Gerald A. Colvin, Suju Zhong, Han Wang, Lionel D'Hondt, Mehrdad Abedi, Angela E. Frimberger, F. Marc Stewart, Peter J. Quesenberry

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Graft rejection and graft-versus-host disease are major problems in mismatched marrow transplants along with toxicity from standard myeloablative host treatments. We have established a tolerization model, using 1 Gy irradiation, which reduces stem cell capacity to < 10% of control while causing minimal myelosuppression, donor antigen pre-exposure (spleen cells), CD40-ligand antibody blockade and high levels of marrow (40 × 106 cells), which allows for stable long-term multilineage engraftment in H2-mismatched murine marrow transplants. We now show that the establishment of 'microchimaerism' (0.5-3.8%) sets the stage for macrochimaerism, with subsequent marrow infusions in H2-mismatched mice with CD40-ligand blockade only. Neither irradiation nor spleen cell exposure were necessary. When 40 × 106 bone marrow cells were infused on weeks 0, 12, 14 and 16, blood engraftment was about seven times the single 40 × 106 control. When marrow cells were given on weeks 0, 3, 4, 5 and 6, engraftment at 24 weeks post transplant was 17.9 ± 1.2%, compared with 2.7 ± 0.8% for the single 40 × 106 control (P = 0.009). We have shown stable, long-term multilineage chimaerism and established that the schedule of marrow administration, not the total cell dose, is critical for tolerization. This approach indicates that microchimaerism can tolerize for subsequent marrow infusions and produce macrochimaerism. This strategy could be applied in clinical human transplants.

Original languageEnglish (US)
Pages (from-to)155-163
Number of pages9
JournalBritish Journal of Haematology
Volume119
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

CD40 Ligand
Transplantation
Bone Marrow
Antibodies
Transplants
Spleen
Graft Rejection
Graft vs Host Disease
Bone Marrow Cells
Appointments and Schedules
Stem Cells
Antigens

Keywords

  • Allograft
  • B7 antigen
  • Bone marrow transplantation
  • Co-stimulation blockade
  • Immune tolerance

ASJC Scopus subject areas

  • Hematology

Cite this

H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. / Lambert, Jean François; Colvin, Gerald A.; Zhong, Suju; Wang, Han; D'Hondt, Lionel; Abedi, Mehrdad; Frimberger, Angela E.; Stewart, F. Marc; Quesenberry, Peter J.

In: British Journal of Haematology, Vol. 119, No. 1, 2002, p. 155-163.

Research output: Contribution to journalArticle

Lambert, JF, Colvin, GA, Zhong, S, Wang, H, D'Hondt, L, Abedi, M, Frimberger, AE, Stewart, FM & Quesenberry, PJ 2002, 'H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation', British Journal of Haematology, vol. 119, no. 1, pp. 155-163. https://doi.org/10.1046/j.1365-2141.2002.03801.x
Lambert, Jean François ; Colvin, Gerald A. ; Zhong, Suju ; Wang, Han ; D'Hondt, Lionel ; Abedi, Mehrdad ; Frimberger, Angela E. ; Stewart, F. Marc ; Quesenberry, Peter J. / H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. In: British Journal of Haematology. 2002 ; Vol. 119, No. 1. pp. 155-163.
@article{248f674755f64977af7770d32b6ba8b9,
title = "H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation",
abstract = "Graft rejection and graft-versus-host disease are major problems in mismatched marrow transplants along with toxicity from standard myeloablative host treatments. We have established a tolerization model, using 1 Gy irradiation, which reduces stem cell capacity to < 10{\%} of control while causing minimal myelosuppression, donor antigen pre-exposure (spleen cells), CD40-ligand antibody blockade and high levels of marrow (40 × 106 cells), which allows for stable long-term multilineage engraftment in H2-mismatched murine marrow transplants. We now show that the establishment of 'microchimaerism' (0.5-3.8{\%}) sets the stage for macrochimaerism, with subsequent marrow infusions in H2-mismatched mice with CD40-ligand blockade only. Neither irradiation nor spleen cell exposure were necessary. When 40 × 106 bone marrow cells were infused on weeks 0, 12, 14 and 16, blood engraftment was about seven times the single 40 × 106 control. When marrow cells were given on weeks 0, 3, 4, 5 and 6, engraftment at 24 weeks post transplant was 17.9 ± 1.2{\%}, compared with 2.7 ± 0.8{\%} for the single 40 × 106 control (P = 0.009). We have shown stable, long-term multilineage chimaerism and established that the schedule of marrow administration, not the total cell dose, is critical for tolerization. This approach indicates that microchimaerism can tolerize for subsequent marrow infusions and produce macrochimaerism. This strategy could be applied in clinical human transplants.",
keywords = "Allograft, B7 antigen, Bone marrow transplantation, Co-stimulation blockade, Immune tolerance",
author = "Lambert, {Jean Fran{\cc}ois} and Colvin, {Gerald A.} and Suju Zhong and Han Wang and Lionel D'Hondt and Mehrdad Abedi and Frimberger, {Angela E.} and Stewart, {F. Marc} and Quesenberry, {Peter J.}",
year = "2002",
doi = "10.1046/j.1365-2141.2002.03801.x",
language = "English (US)",
volume = "119",
pages = "155--163",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation

AU - Lambert, Jean François

AU - Colvin, Gerald A.

AU - Zhong, Suju

AU - Wang, Han

AU - D'Hondt, Lionel

AU - Abedi, Mehrdad

AU - Frimberger, Angela E.

AU - Stewart, F. Marc

AU - Quesenberry, Peter J.

PY - 2002

Y1 - 2002

N2 - Graft rejection and graft-versus-host disease are major problems in mismatched marrow transplants along with toxicity from standard myeloablative host treatments. We have established a tolerization model, using 1 Gy irradiation, which reduces stem cell capacity to < 10% of control while causing minimal myelosuppression, donor antigen pre-exposure (spleen cells), CD40-ligand antibody blockade and high levels of marrow (40 × 106 cells), which allows for stable long-term multilineage engraftment in H2-mismatched murine marrow transplants. We now show that the establishment of 'microchimaerism' (0.5-3.8%) sets the stage for macrochimaerism, with subsequent marrow infusions in H2-mismatched mice with CD40-ligand blockade only. Neither irradiation nor spleen cell exposure were necessary. When 40 × 106 bone marrow cells were infused on weeks 0, 12, 14 and 16, blood engraftment was about seven times the single 40 × 106 control. When marrow cells were given on weeks 0, 3, 4, 5 and 6, engraftment at 24 weeks post transplant was 17.9 ± 1.2%, compared with 2.7 ± 0.8% for the single 40 × 106 control (P = 0.009). We have shown stable, long-term multilineage chimaerism and established that the schedule of marrow administration, not the total cell dose, is critical for tolerization. This approach indicates that microchimaerism can tolerize for subsequent marrow infusions and produce macrochimaerism. This strategy could be applied in clinical human transplants.

AB - Graft rejection and graft-versus-host disease are major problems in mismatched marrow transplants along with toxicity from standard myeloablative host treatments. We have established a tolerization model, using 1 Gy irradiation, which reduces stem cell capacity to < 10% of control while causing minimal myelosuppression, donor antigen pre-exposure (spleen cells), CD40-ligand antibody blockade and high levels of marrow (40 × 106 cells), which allows for stable long-term multilineage engraftment in H2-mismatched murine marrow transplants. We now show that the establishment of 'microchimaerism' (0.5-3.8%) sets the stage for macrochimaerism, with subsequent marrow infusions in H2-mismatched mice with CD40-ligand blockade only. Neither irradiation nor spleen cell exposure were necessary. When 40 × 106 bone marrow cells were infused on weeks 0, 12, 14 and 16, blood engraftment was about seven times the single 40 × 106 control. When marrow cells were given on weeks 0, 3, 4, 5 and 6, engraftment at 24 weeks post transplant was 17.9 ± 1.2%, compared with 2.7 ± 0.8% for the single 40 × 106 control (P = 0.009). We have shown stable, long-term multilineage chimaerism and established that the schedule of marrow administration, not the total cell dose, is critical for tolerization. This approach indicates that microchimaerism can tolerize for subsequent marrow infusions and produce macrochimaerism. This strategy could be applied in clinical human transplants.

KW - Allograft

KW - B7 antigen

KW - Bone marrow transplantation

KW - Co-stimulation blockade

KW - Immune tolerance

UR - http://www.scopus.com/inward/record.url?scp=0036402128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036402128&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03801.x

DO - 10.1046/j.1365-2141.2002.03801.x

M3 - Article

VL - 119

SP - 155

EP - 163

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -